Drug discovery & development

Client: Theryte Ltd, an oncology drug discovery company spin-out from the University of Liverpool

Ithaka's role:

  • To provide management services to Theryte since February 2007 to assist the founder in commercialising his technology. Dr Bill Primrose of Ithaka was part-time CEO of Theryte and led the development of a new business plan, negotiations of deals with key CROs and collaborations with other research organisations. He also managed the R&D, including out-sourcing target identification, synthetic chemistry, pharmacokinetics, toxicology and in vivo studies.

Results:

  • Dr Bill Primrose has obtained further equity financing for the business from new angel investors and existing investors, and grant funding to complete a set of experiments designed to demonstrate proof-of-concept for Theryte's lead molecule.

Client: NVM Private Equity / YFM Private Equity and Gentronix

Ithaka's role:

  • To perform two business and technical due diligence assessments on Gentronix, a University of Manchester spin-out developing novel toxicology tests for use in pharmaceutical development.

Results:

  • Investment of over £1M into Gentronix.